Bovine Sourcing and TSE Risk: Answering Hospital Safety Questions

Hospitals ask about bovine sourcing and TSE risk because collagen dural grafts are animal-derived implants placed next to the brain or spinal cord. The right answer explains the control framework, the ISO 22442 series covering sourcing, risk management and process validation, and offers the manufacturer's documentation. It never claims zero risk and never guesses.

These questions come up in almost every account that evaluates a collagen dural graft. They are not hostile. They reflect the history of bovine spongiform encephalopathy and the earlier experience with human cadaveric dura grafts, which were linked to transmission of Creutzfeldt-Jakob disease and largely abandoned. This article is a practical guide for distributors: who asks, what they want to know and how to respond for DESU's DURASHEET and DECOLL. For the technical background, read our article on bovine collagen safety.

Who asks, and why?

Different people in a hospital ask about animal origin for different reasons. Recognizing the reason helps you give the right answer.

The underlying framework is the same in every case. The level of detail and the emphasis differ.

What are the questions you will hear most often?

The questions below come up repeatedly. Prepare a short answer to each, and know which document supports it.

"What animal and what tissue does the collagen come from?"

DESU's collagen dural grafts are made from pure Type I bovine collagen. Details of the tissue source and its origin are part of the manufacturer's sourcing documentation; ask DESU for the summary rather than describing it from memory.

"How is BSE risk controlled?"

Through a combination of measures defined in the ISO 22442 series: risk management for the animal material, controls on the origin, collection and handling of the animals and tissue, and validation of manufacturing steps that reduce viruses and TSE agents. In the European framework, Commission Regulation (EU) No 722/2012 sets specific requirements for devices made with animal tissue.

"Can you guarantee there is no risk?"

No responsible supplier makes that claim. The aim of the framework is to reduce residual risk to a level that is acceptable when weighed against clinical benefit, and to document the reasoning. Say so plainly. Reviewers trust that answer far more than an absolute promise.

"Is the material traceable?"

Traceability runs in two directions: from the finished device back to its raw material lot, which is the manufacturer's responsibility, and from the device to the patient, through the lot number recorded in the implant record. Both are part of a well-run system.

"How is the product sterilized?"

DURASHEET and DECOLL are gamma sterilized and supplied ready to use. Sterilization addresses conventional microbial contamination; TSE risk is managed through sourcing and processing, which is why both are documented.

"Where is the product made?"

DESU designs and manufactures DURASHEET and DECOLL in its own cleanrooms in Ankara, Türkiye, under an ISO 13485 quality management system. Reviewers sometimes ask this to understand whether the manufacturer controls the process directly; in DESU's case, it does.

"Has anyone independent reviewed these controls?"

Under the European framework for CE marking, devices made from non-viable animal tissue are placed in the highest risk class and their conformity assessment involves a notified body, which reviews the manufacturer's risk assessment, sourcing controls and process validation. The CE certificate identifies the notified body. This gives reviewers an external reference point beyond the manufacturer's own statements.

What should you never say?

Some answers damage trust immediately. Avoid them, even when under pressure in a meeting:

• "There is zero risk." No biological material can be described that way.
• "It is the same as every other collagen product." Products differ in sourcing and processing.
• "I am sure it is fine." Opinion is not documentation.
• "Other suppliers have had problems." Never discuss competitors' safety.
• A guess at the country of origin, the tissue type or a process step you have not confirmed with DESU.

When you do not know, say "I will get you the manufacturer's answer in writing," and do it promptly.

How should you escalate a detailed question?

Some reviewers ask questions that go beyond a summary: specific process steps, validation methods or certificates for raw material suppliers. Treat these as a normal part of due diligence:

• Write down the exact question, in the reviewer's words.
• Send it to DESU with the account name and the deadline.
• Ask whether the answer can be shared in writing and whether any of it is confidential.
• Deliver the answer as received, without rewording technical content.
• Record the question and answer for future accounts.

DESU, as the manufacturer, holds the technical documentation and can answer these questions directly. That is one of the practical advantages of working with a manufacturer rather than a trading intermediary.

How do you support surgeons in their consent conversations?

Surgeons need to explain the graft to patients in simple terms. They may ask you for a sentence they can use. Something factual and modest works best: "The graft is made from purified collagen of bovine origin, processed and sterilized under international standards for animal-derived medical devices."

Do not script the consent conversation itself; that is the surgeon's responsibility. If a patient declines an animal-derived implant, the surgeon will discuss alternatives. Make sure the surgeon knows that both DESU membranes, DURASHEET and DECOLL, are of bovine origin, so that the information is accurate.

How do the questions differ between hospitals?

Academic medical centers tend to ask the most detailed questions, sometimes through a formal biologics or implant review alongside value analysis. Community hospitals often ask fewer questions but want a concise summary they can file. Children's hospitals may focus on the clarity of disclosure for families. Hospitals that serve communities with specific religious or dietary practices may ask particularly about how the animal source is communicated to patients.

None of these differences change the facts. They change how much detail you bring and how you present it. A one-page summary with the full documents available on request works for most accounts; an academic center may want the documents up front.

Why does preparing in advance matter?

An account that asks about TSE risk and receives a clear, documented answer within a day tends to move forward. An account that waits two weeks for a vague reply tends to stall. Preparation turns a potential obstacle into a demonstration of competence.

Build a small reference set for each product: the sourcing and TSE summary, the biological evaluation summary, the sterilization summary and the certificates. Keep the current versions on file, and check with DESU periodically that nothing has changed.

Talk to a DESU product specialist

If hospitals in your territory are asking about bovine sourcing and TSE controls for collagen dural grafts, DESU's product specialists can provide the documentation for DURASHEET and DECOLL, answer detailed technical questions and discuss your market's requirements. Contact sales@desu.tr, use the contact page, or request a quote.